EUTECNIQAtlas

Every page of EUTECNIQ on one mapArrow keys move through results · Enter opens · Esc closes

Reference library Drugs@FDA, FDA labels, EMA, SEC filings Peer-reviewed histories

Plant to prescription

Medicines whose starting molecule came from a plant, a fungus or a marine animal, with the approval dates, labeled uses and sales figures from the regulator or the company filing. Many are now made by semi-synthesis, synthesis or fermentation; the organism supplied the lead.

>$9 billionworldwide Taxol (paclitaxel) sales by Bristol-Myers Squibb, 1993 through 2002 (GAO)
62 of 185small-molecule cancer drugs approved January 1981 to September 2019 counted as natural products or derived from them (the authors' N* categories)
4botanical drugs approved by FDA under an NDA or BLA, 2006–2023
2015Nobel Prize to Tu Youyou for the malaria therapy that became artemisinin, from Artemisia annua

GAO-03-829 (June 2003), p. 4; Newman DJ, Cragg GM. J Nat Prod 2020;83:770–803, abstract; FDA, “What is a Botanical Drug?” (content current as of September 3, 2026); Ther Innov Regul Sci 2025 (FDA authors); Nobel Assembly press release, October 5, 2015.

Status. EUTECNIQ is in formation and has no laboratory, products or drug programs. This page records what regulators, companies and historians have published about other people's medicines. Nothing here is medical advice; indications are summarized from the current US label.

Related: History of botanical medicine · The claims gap · Pipeline · Bioactive compounds

Chronology

Thirty-two milestones, 1805 to 2023

Each row is a dated event: an isolation or discovery reported in a peer-reviewed history, a Nobel Prize, or an original approval in Drugs@FDA (FDA) or by the European Commission (EU). Choose a source organism to bring its rows forward.

Show source
Plants supplied most of these leads; fungi gave penicillin, a statin and a transplant drug; marine drugs arrived after 2000Drugs@FDA, EMA, Nobel
Chronology of 32 medicines and milestones that began in plants, fungi and marine organisms, from morphine (1805) to birch triterpenes (2023)PlantFungusMarine organism1805: Morphine reported (Sertürner; opium poppy juice)1805Morphine reportedSertürner; opium poppy juice1820: Quinine isolated (Pelletier and Caventou; cinchona bark)1820Quinine isolatedPelletier and Caventou; cinchona bark1897: Acetylsalicylic acid made (Hoffmann at Bayer; willow salicylates)1897Acetylsalicylic acid madeHoffmann at Bayer; willow salicylates1928: Penicillin effect observed (Fleming; Penicillium notatum)1928Penicillin effect observedFleming; Penicillium notatum1945: Nobel Prize for penicillin (Fleming, Chain and Florey)1945Nobel Prize for penicillinFleming, Chain and Florey1954: Digoxin, FDA (NDA 009330) (Digitalis lanata leaf)1954Digoxin, FDA (NDA 009330)Digitalis lanata leaf1957: Metformin first used in diabetes (Sterne; Galega officinalis lineage)1957Metformin first used in diabetesSterne; Galega officinalis lineage1963: Vincristine, FDA (Catharanthus roseus)1963Vincristine, FDACatharanthus roseus1965: Vinblastine, FDA (Catharanthus roseus)1965Vinblastine, FDACatharanthus roseus1972: Artemisinin purified (Tu Youyou; Artemisia annua)1972Artemisinin purifiedTu Youyou; Artemisia annua1979: Monacolin K isolated (Endo; Monascus ruber)1979Monacolin K isolatedEndo; Monascus ruber1983: Etoposide, FDA (podophyllotoxin derivative)1983Etoposide, FDApodophyllotoxin derivative1983: Cyclosporine, FDA (Beauveria nivea)Cyclosporine, FDABeauveria nivea1987: Lovastatin, FDA (Aspergillus terreus)1987Lovastatin, FDAAspergillus terreus1992: Paclitaxel, FDA (Taxus brevifolia)1992Paclitaxel, FDATaxus brevifolia1995: Metformin, FDA (Glucophage)1995Metformin, FDAGlucophage1996: Topotecan and irinotecan, FDA (camptothecin; Camptotheca acuminata)1996Topotecan and irinotecan, FDAcamptothecin; Camptotheca acuminata2001: Galantamine, FDA (Amaryllidaceae alkaloid)2001Galantamine, FDAAmaryllidaceae alkaloid2004: Ziconotide, FDA (conopeptide; Conus magus)2004Ziconotide, FDAconopeptide; Conus magus2005: Quinine sulfate, FDA (Qualaquin)2005Quinine sulfate, FDAQualaquin2006: Sinecatechins, FDA (botanical drug; Camellia sinensis)2006Sinecatechins, FDAbotanical drug; Camellia sinensis2007: Trabectedin, EU (first isolated from a tunicate)2007Trabectedin, EUfirst isolated from a tunicate2009: Artemether–lumefantrine, FDA (artemisinin derivative)2009Artemether–lumefantrine, FDAartemisinin derivative2009: Colchicine (Colcrys), FDA (Colchicum autumnale alkaloid)Colchicine (Colcrys), FDAColchicum autumnale alkaloid2009: Capsaicin 8% patch, FDA (synthetic chili-pepper compound)Capsaicin 8% patch, FDAsynthetic chili-pepper compound2010: Eribulin, FDA (halichondrin B analogue; sponge)2010Eribulin, FDAhalichondrin B analogue; sponge2012: Crofelemer, FDA (botanical drug; Croton lechleri)2012Crofelemer, FDAbotanical drug; Croton lechleri2015: Nobel Prize for artemisinin (Tu Youyou)2015Nobel Prize for artemisininTu Youyou2015: Trabectedin, FDA (liposarcoma, leiomyosarcoma)Trabectedin, FDAliposarcoma, leiomyosarcoma2018: Cannabidiol (Epidiolex), FDA (Cannabis sativa)2018Cannabidiol (Epidiolex), FDACannabis sativa2022: Anacaulase-bcdb, FDA (BLA) (botanical drug; pineapple stem)2022Anacaulase-bcdb, FDA (BLA)botanical drug; pineapple stem2023: Birch triterpenes, FDA (botanical drug; Betula bark)2023Birch triterpenes, FDAbotanical drug; Betula barkChronology of 32 medicines and milestones that began in plants, fungi and marine organisms, from morphine (1805) to birch triterpenes (2023)PlantFungusMarine organism1805: Morphine reported (Sertürner; opium poppy juice)1805Morphine reportedSertürner; opium poppy juice1820: Quinine isolated (Pelletier and Caventou; cinchona bark)1820Quinine isolatedPelletier and Caventou; cinchona bark1897: Acetylsalicylic acid made (Hoffmann at Bayer; willow salicylates)1897Acetylsalicylic acid madeHoffmann at Bayer; willow salicylates1928: Penicillin effect observed (Fleming; Penicillium notatum)1928Penicillin effect observedFleming; Penicillium notatum1945: Nobel Prize for penicillin (Fleming, Chain and Florey)1945Nobel Prize for penicillinFleming, Chain and Florey1954: Digoxin, FDA (NDA 009330) (Digitalis lanata leaf)1954Digoxin, FDA (NDA 009330)Digitalis lanata leaf1957: Metformin first used in diabetes (Sterne; Galega officinalis lineage)1957Metformin first used in diabetesSterne; Galega officinalis lineage1963: Vincristine, FDA (Catharanthus roseus)1963Vincristine, FDACatharanthus roseus1965: Vinblastine, FDA (Catharanthus roseus)1965Vinblastine, FDACatharanthus roseus1972: Artemisinin purified (Tu Youyou; Artemisia annua)1972Artemisinin purifiedTu Youyou; Artemisia annua1979: Monacolin K isolated (Endo; Monascus ruber)1979Monacolin K isolatedEndo; Monascus ruber1983: Etoposide, FDA (podophyllotoxin derivative)1983Etoposide, FDApodophyllotoxin derivative1983: Cyclosporine, FDA (Beauveria nivea)Cyclosporine, FDABeauveria nivea1987: Lovastatin, FDA (Aspergillus terreus)1987Lovastatin, FDAAspergillus terreus1992: Paclitaxel, FDA (Taxus brevifolia)1992Paclitaxel, FDATaxus brevifolia1995: Metformin, FDA (Glucophage)1995Metformin, FDAGlucophage1996: Topotecan and irinotecan, FDA (camptothecin; Camptotheca acuminata)1996Topotecan and irinotecan, FDAcamptothecin; Camptotheca acuminata2001: Galantamine, FDA (Amaryllidaceae alkaloid)2001Galantamine, FDAAmaryllidaceae alkaloid2004: Ziconotide, FDA (conopeptide; Conus magus)2004Ziconotide, FDAconopeptide; Conus magus2005: Quinine sulfate, FDA (Qualaquin)2005Quinine sulfate, FDAQualaquin2006: Sinecatechins, FDA (botanical drug; Camellia sinensis)2006Sinecatechins, FDAbotanical drug; Camellia sinensis2007: Trabectedin, EU (first isolated from a tunicate)2007Trabectedin, EUfirst isolated from a tunicate2009: Artemether–lumefantrine, FDA (artemisinin derivative)2009Artemether–lumefantrine, FDAartemisinin derivative2009: Colchicine (Colcrys), FDA (Colchicum autumnale alkaloid)Colchicine (Colcrys), FDAColchicum autumnale alkaloid2009: Capsaicin 8% patch, FDA (synthetic chili-pepper compound)Capsaicin 8% patch, FDAsynthetic chili-pepper compound2010: Eribulin, FDA (halichondrin B analogue; sponge)2010Eribulin, FDAhalichondrin B analogue; sponge2012: Crofelemer, FDA (botanical drug; Croton lechleri)2012Crofelemer, FDAbotanical drug; Croton lechleri2015: Nobel Prize for artemisinin (Tu Youyou)2015Nobel Prize for artemisininTu Youyou2015: Trabectedin, FDA (liposarcoma, leiomyosarcoma)Trabectedin, FDAliposarcoma, leiomyosarcoma2018: Cannabidiol (Epidiolex), FDA (Cannabis sativa)2018Cannabidiol (Epidiolex), FDACannabis sativa2022: Anacaulase-bcdb, FDA (BLA) (botanical drug; pineapple stem)2022Anacaulase-bcdb, FDA (BLA)botanical drug; pineapple stem2023: Birch triterpenes, FDA (botanical drug; Betula bark)2023Birch triterpenes, FDAbotanical drug; Betula bark
Approval dates: Drugs@FDA original approvals (application numbers in the table below); trabectedin EU date: EMA EPAR. Discoveries: Krishnamurti and Rao 2016 (morphine); Achan et al. 2011 (quinine); Montinari et al. 2019 (acetylsalicylic acid); Fleming, Nobel lecture 1945 and Nobel biography (penicillin); Bailey 2017 (metformin); Nobel Assembly 2015 and Liu and Liu 2016 (artemisinin); Endo 2010 (monacolin K). Showing all 32 events.
Reference table

Organism, compound and approved drug

Twenty-two approved medicines, each traced to its source organism. The approval column gives the original approval of the named application in Drugs@FDA, or the European Commission date for the EU. The indication column summarizes the current US label, which is often broader than the first approval.

Source organism, compound, drug, first approval, labeled indication and source for 22 medicines from plants, fungi and marine organisms
OrganismCompoundDrug (brand)First approval (agency, year)Indication, current US label (summary)Source
Plants
Taxus brevifolia (bark of the original isolation)PaclitaxelTaxolFDA, 1992 (NDA 020262)Advanced ovarian carcinoma; adjuvant node-positive breast cancer; breast cancer after failed combination chemotherapy; first-line non-small cell lung cancer with cisplatin; second-line AIDS-related Kaposi's sarcomaDrugs@FDA; paclitaxel label; Wall 1998
Catharanthus roseusVincristineOncovinFDA, 1963 (NDA 014103)Acute leukemia; combination use in Hodgkin's disease, non-Hodgkin lymphomas, rhabdomyosarcoma, neuroblastoma, Wilms' tumorDrugs@FDA; vincristine label
Catharanthus roseusVinblastineVelbanFDA, 1965 (NDA 012665)Palliative treatment of Hodgkin's disease, lymphomas, testicular carcinoma, Kaposi's sarcoma and other listed malignanciesDrugs@FDA; vinblastine label
Digitalis lanata (leaf)DigoxinLanoxinFDA, 1954 (NDA 009330)Mild to moderate heart failure in adults; heart failure in children; ventricular rate control in chronic atrial fibrillationDrugs@FDA; Lanoxin label
Galega officinalis (galegine lineage)Metformin (synthetic biguanide)GlucophageFDA, 1995 (NDA 020357)Glycemic control in type 2 diabetes, adults and children 10 years and olderDrugs@FDA; metformin label; Bailey 2017; Hadden 2005
Artemisia annuaArtemether (artemisinin derivative) with lumefantrineCoartemFDA, 2009 (NDA 022268)Acute, uncomplicated Plasmodium falciparum malaria, patients 2 months and older and at least 5 kgDrugs@FDA; Coartem label
Cinchona barkQuinineQualaquinFDA, 2005 (NDA 021799)Uncomplicated P. falciparum malaria only; label excludes nocturnal leg crampsDrugs@FDA; quinine sulfate label; Achan 2011
Galanthus and other AmaryllidaceaeGalantamineRazadyneFDA, 2001 (NDA 021169)Mild to moderate dementia of the Alzheimer's typeDrugs@FDA; galantamine label; Heinrich 2010
Colchicum autumnaleColchicineColcrysFDA, 2009 (NDA 022352)Prophylaxis and treatment of gout flares in adults; familial Mediterranean fever, age 4 and olderDrugs@FDA; Colcrys label; Dasgeb 2018
Podophyllin-yielding plantsEtoposide (from podophyllotoxin)VePesidFDA, 1983 (NDA 018768)Refractory testicular tumors; first-line small cell lung cancer, in combinationDrugs@FDA; etoposide label; Hande 1998
Camptotheca acuminataTopotecan (camptothecin analogue)HycamtinFDA, 1996 (NDA 020671)Injection: metastatic ovarian cancer after progression on or after chemotherapy; platinum-sensitive small cell lung cancer that progressed at least 60 days after first-line chemotherapy; stage IV-B, recurrent or persistent cervical cancer, with cisplatinDrugs@FDA; Hycamtin label; Wall 1998
Camptotheca acuminataIrinotecan (camptothecin analogue)CamptosarFDA, 1996 (NDA 020571)Metastatic colorectal carcinoma, first-line with 5-FU and leucovorin, or after fluorouracil-based therapyDrugs@FDA; Camptosar label; Wall 1998
Chili peppersCapsaicin (synthetic equivalent)QutenzaFDA, 2009 (NDA 022395)Neuropathic pain of postherpetic neuralgia and of diabetic peripheral neuropathy of the feet, adultsDrugs@FDA; Qutenza label
Cannabis sativaCannabidiolEpidiolexFDA, 2018 (NDA 210365)Seizures of Lennox-Gastaut syndrome, Dravet syndrome or tuberous sclerosis complex, age 1 and olderDrugs@FDA; Epidiolex label
Camellia sinensis (leaf)Sinecatechins (botanical drug substance)VeregenFDA, 2006 (NDA 021902)External genital and perianal warts, immunocompetent patients 18 and olderDrugs@FDA; Veregen label
Croton lechleri (red latex)Crofelemer (botanical drug substance)MytesiFDA, 2012 (NDA 202292)Symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapyDrugs@FDA; Mytesi label
Ananas comosus (stem)Anacaulase-bcdb (botanical drug substance)NexoBridFDA, 2022 (BLA 761192)Eschar removal in deep partial-thickness and full-thickness thermal burnsDrugs@FDA; NexoBrid label
Betula pendula, B. pubescens (bark)Birch triterpenes (botanical drug substance)FilsuvezFDA, 2023 (NDA 215064)Wounds of dystrophic and junctional epidermolysis bullosa, age 6 months and olderDrugs@FDA; Filsuvez label
Fungi
Aspergillus terreus (also Monascus ruber, as monacolin K)LovastatinMevacorFDA, 1987 (NDA 019643)Dyslipidemia; reduction of coronary heart disease risk, with dietDrugs@FDA; lovastatin label; Endo 2010
Beauveria niveaCyclosporineSandimmuneFDA, 1983 (NDA 050573)Prophylaxis of organ rejection in kidney, liver and heart transplants, with corticosteroidsDrugs@FDA; Sandimmune label
Marine organisms
Tunicate (sea squirt)Trabectedin (synthetic)YondelisEU, 2007; FDA, 2015 (NDA 207953)Unresectable or metastatic liposarcoma or leiomyosarcoma after an anthracyclineEMA EPAR; Drugs@FDA; Yondelis label
Conus magus (cone snail)Ziconotide (synthetic conopeptide)PrialtFDA, 2004 (NDA 021060)Severe chronic pain needing intrathecal therapy, when other treatment fails or is not toleratedDrugs@FDA; Prialt label
Halichondria okadai (sponge)Eribulin (synthetic halichondrin B analogue)HalavenFDA, 2010 (NDA 201532)Metastatic breast cancer after two or more regimens; unresectable or metastatic liposarcomaDrugs@FDA; Halaven label

Drugs@FDA application overview pages and the current labels on DailyMed (openFDA label records), opened October 28, 2026. Heinrich M. Alkaloids Chem Biol 2010;68:157–165 (galantamine). Hande KR. Eur J Cancer 1998;34:1514–1521 (etoposide). Several originator brands are discontinued; generic labels were used where the brand label is no longer posted. EU trabectedin indications (soft-tissue sarcoma; relapsed platinum-sensitive ovarian cancer with pegylated liposomal doxorubicin): EMA EPAR.

Plants

Artemisinin and an extraction step

Tu Youyou's group screened herbal remedies in malaria-infected animals. An Artemisia annua extract gave 12–40% parasite inhibition, inconsistently. A recipe by Ge Hong described taking the juice of the leaves with cold water rather than by boiling; Tu switched from ethanol to a cold ether extraction and obtained 100% parasite killing in infected mice and monkeys.

The active component, artemisinin, was isolated and its structure established afterward. The first FDA-approved product containing an artemisinin derivative in this table is artemether–lumefantrine (2009).

Steps from the Artemisia annua extract to an approved artemisinin-derivative medicine
YearStepRecord
1969Tu Youyou heads a group in the national malaria project (Project 523)Peer-reviewed histories (source line)
1971Antimalarial activity of A. annua extractsPeer-reviewed histories
1972Artemisinin purifiedPeer-reviewed histories
2009Artemether–lumefantrine (Coartem) approved, uncomplicated P. falciparum malariaDrugs@FDA, NDA 022268
2011Lasker Award to Tu YouyouPeer-reviewed histories
2015Half of the Nobel Prize in Physiology or Medicine, “for her discoveries concerning a novel therapy against Malaria”Nobel Assembly, October 5, 2015

Nobel Assembly at Karolinska Institutet, press release and scientific background, 2015 (12–40% inhibition; Ge Hong; cold ether extraction; 100% in mice and monkeys). Liu W, Liu Y. Cardiovasc Diagn Ther 2016;6:1–2, and [authors, title, journal, year;volume:pages] (PMC6139675) (dates for 1969, 1971, 1972 and the 2011 Lasker Award). The Nobel background dates Ge Hong's recipes to 340 AD. The other half of the 2015 prize went to William C. Campbell and Satoshi Ōmura for avermectin.

Plants

Paclitaxel, supply and sales

Paclitaxel was isolated from Taxus brevifolia. FDA approved Taxol on December 29, 1992, for ovarian cancer after failure of first-line or later chemotherapy, and in 1994 for breast cancer. Bristol-Myers Squibb's 1996 annual report credited “a semi-synthetic material” with lower production costs; a current generic label states that paclitaxel is obtained by a semi-synthetic process from Taxus baccata.

Sales passed $1 billion in 1998 and fell 25% in 2001, when the company attributed the decline to generic competition.

Taxol sales kept rising for three years after US exclusivity ended and then fell by a quarter in 2001, when the company cited generic competitionSEC Form 10-K
Bar chart of Taxol (paclitaxel) annual sales reported by Bristol-Myers Squibb, 1995 to 2002, in millions of US dollars: rising from 580 in 1995 to 1,592 in 2000 and falling to 1,197 in 2001 after generic competition05001,0001,5002,000US$ million1995: $580 million (as first reported)5801996: $813 million (as first reported)8131997: $941 million (as first reported)9411998: $1,206 million (as first reported)1,2061999: $1,481 million (as first reported)1,4812000: $1,592 million (as first reported)1,5922001: $1,197 million (as first reported)1,1972001: $1,112 million (FY2002 10-K basis)1,1122002: $857 million (FY2002 10-K basis)85719951996199719981999200020012002US exclusivityended Dec 1997genericcompetitionas first reported (10-K for that year or the next)FY2002 10-K restated basisBar chart of Taxol (paclitaxel) annual sales reported by Bristol-Myers Squibb, 1995 to 2002, in millions of US dollars: rising from 580 in 1995 to 1,592 in 2000 and falling to 1,197 in 2001 after generic competition05001,0001,5002,000US$ million1995: $580 million (as first reported)5801996: $813 million (as first reported)8131997: $941 million (as first reported)9411998: $1,206 million (as first reported)1,2061999: $1,481 million (as first reported)1,4812000: $1,592 million (as first reported)1,5922001: $1,197 million (as first reported)2001: $1,112 million (FY2002 10-K basis)2002: $857 million (FY2002 10-K basis)8571,197’95’96’97’98’99’00’01’02US exclusivityended 1997genericcompetitionas first reportedFY2002 10-K restated basis
Bristol-Myers Squibb Form 10-K: FY1995 ($580 million), FY1996 ($813 million; exclusivity “expiring in December 1997”), FY1999 product table (1997–1999), FY2001 product table (2000–2001; “TAXOL and BUSPAR sales declined due to generic competition”), FY2002 table on its restated basis (2001 $1,112 million; 2002 $857 million). SEC EDGAR, CIK 0000014272.
Figures on Taxol from the US General Accounting Office report GAO-03-829
Measure (GAO-03-829)Value
BMS worldwide Taxol sales, 1993 through 2002Over $9 billion
BMS's stated cost to develop Taxol$1 billion (company officials)
Medicare payments for Taxol, 1994 through 1999$687 million
NIH royalty payments through 2002$35 million
Florida State University royalty rate (GAO estimate)About 4.2% of worldwide sales

US General Accounting Office. Technology Transfer: NIH–Private Sector Partnership in the Development of Taxol. GAO-03-829, June 4, 2003, p. 4 and p. 13, footnote 17. Wall ME. Med Res Rev 1998;18:299–314 (isolation from T. brevifolia). BMS Form 10-K FY1996 (1992 and 1994 US clearances; semi-synthetic material). Paclitaxel injection label, ANDA 216874 (T. baccata).

Plants

Old remedies, later approvals

Several plant medicines were isolated or in use long before modern drug approval. FDA's records show what happened later: Lanoxin tablets (1997) and Colcrys (2009) were approved as “Type 7 – drug already marketed without approved NDA,” the category for products sold before an application was approved.

Plant medicines: early record and later approval record
PlantCompoundEarly recordApproval record
Opium poppyMorphineSertürner reported a sleep-inducing crystalline substance from poppy juice in 1805; his work led to the isolation of other alkaloids, codeine among themNot reviewed for this page
Cinchona barkQuinineExtracted, isolated and named in 1820 by Pelletier and Caventou; bark used against malaria from the 1600sQualaquin, FDA 2005 (NDA 021799)
Willow (bark salicylates)Acetylsalicylic acidWillow bark used as a painkiller and antipyretic for more than 3,500 years; synthesized by Bayer chemist Felix Hoffmann in 1897Not reviewed for this page
Galega officinalis (goat's rue)Guanidine, galegine → metforminPlant rich in guanidine, shown in 1918 to lower blood glucose; metformin first reported for diabetes by Jean Sterne in 1957Glucophage, FDA March 3, 1995 (NDA 020357)
Digitalis lanataDigoxinExtracted from the leaves (label)NDA 009330, 1954; Lanoxin tablets NDA 020405, 1997, Type 7
Colchicum autumnaleColchicineUsed for gout for more than a millenniumColcrys, FDA July 2009 (NDAs 022351, 022352), Type 7

Krishnamurti C, Rao SC. Indian J Anaesth 2016;60:861–862; Achan J, et al. Malar J 2011;10:144; Montinari MR, Minelli S, De Caterina R. Vascul Pharmacol 2019;113:1–8, abstract; Bailey CJ. Diabetologia 2017;60:1566–1576, abstract; Hadden DR. J R Coll Physicians Edinb 2005;35:258–260 (“metformin is derived from galegine”); Dasgeb B, et al. Br J Dermatol 2018;178:350–356, abstract; Kovács-Ábrahám Z, et al. Toxics 2026;14:309 (C. autumnale contains colchicine); Drugs@FDA submission classifications.

Manufacture

The organism gave the lead, not the supply

An approved drug that began in nature is often made another way. The labels below state how each drug substance is obtained today. Semi-synthesis starts from a harvested intermediate; total synthesis and peptide synthesis need no organism; fermentation grows the producing fungus.

How each drug substance is obtained, in the words of its label
DrugNatural originHow the label describes the drug substanceRoute
PaclitaxelTaxus brevifolia“obtained via a semi-synthetic process from Taxus baccata”Semi-synthesis
EtoposidePodophyllotoxin“a semisynthetic derivative of podophyllotoxin”Semi-synthesis
EribulinHalichondria okadai“a synthetic analogue of halichondrin B, a product isolated from the marine sponge”Total synthesis
TrabectedinTunicate“a synthetic version of a substance that was originally extracted from a species of tunicate or ‘sea squirt’” (EMA)Synthesis
ZiconotideConus magus“a synthetic equivalent of a naturally occurring conopeptide”; 25 amino acids, three disulfide bridgesPeptide synthesis
Capsaicin (Qutenza)Chili peppers“a synthetic equivalent of the naturally occurring compound found in chili peppers”Synthesis
LovastatinAspergillus terreus“isolated from a strain of Aspergillus terreus”Fermentation
CyclosporineBeauveria nivea“produced as a metabolite by the fungus species Beauveria nivea”Fermentation
DigoxinDigitalis lanata“extracted from the leaves of Digitalis lanata”Extraction
VinblastineCatharanthus roseus“the salt of an alkaloid extracted from Vinca rosea Linn.”Extraction

Description sections (section 11 or “Description”) of the current US labels on DailyMed; EMA EPAR summary for Yondelis. “Route” is this page's classification of the label wording.

Marine organisms

Medicines from the sea

The three marine-derived drugs in the table are made without harvesting. Ziconotide reproduces a cone-snail peptide that blocks N-type calcium channels and is given intrathecally. Eribulin is a synthetic analogue of halichondrin B, isolated from a sponge. Trabectedin, first isolated from a tunicate, was authorized in the EU in 2007 and by FDA in 2015.

Newman and Cragg note that a significant number of natural-product drugs and leads are produced by microbes, or by microbes interacting with the host from which they were isolated.

Marine-derived medicines: organism, molecule type and approvals
DrugOrganismMoleculeApprovals
Ziconotide (Prialt)Cone snail, Conus magusPeptide, C102H172N36O32S7, 2,639 DaFDA December 28, 2004
Trabectedin (Yondelis)TunicateAlkylating drug, C39H43N3O11S, 761.84 DaEU September 17, 2007; FDA October 23, 2015
Eribulin (Halaven)Sponge, Halichondria okadaiHalichondrin B analogue, mesylate salt 826.0 Da (free base 729.9)FDA November 15, 2010

Prialt, Yondelis and Halaven labels (Description); Drugs@FDA NDAs 021060, 207953, 201532; EMA EPAR, Yondelis (authorization valid throughout the EU, September 17, 2007); Newman DJ, Cragg GM. J Nat Prod 2020;83:770–803, abstract.

Fungi

Medicines from fungi, and red yeast rice

In 1928 Fleming saw a mold clear a staphylococcus plate; the mold was identified as Penicillium notatum, and the 1945 Nobel Prize went to Fleming, Chain and Florey. Akira Endo found compactin in Penicillium citrinum in 1972 and, in February 1979, monacolin K in Monascus ruber; the same year it proved identical to Merck's mevinolin from Aspergillus terreus, later named lovastatin.

FDA approved lovastatin as a new drug in 1987. Red yeast rice products with enhanced or added lovastatin therefore cannot be marketed as dietary supplements in the United States.

Red yeast rice brands varied more than 60-fold in monacolin K, and the highest sat below the lowest labeled lovastatin doseNCCIH; FDA label
Log-scale chart: monacolin K measured in 26 US red yeast rice brands, 0.09 to 5.48 mg per 1,200 mg of product, against the lovastatin label's dosing range of 10 to 80 mg per dayRed yeast rice, 26 brandsmonacolin K per 1,200 mg productRed yeast rice, 26 brands: 0.09–5.48 mg0.095.48Lovastatin labelrange per day; starting dose 20 mgLovastatin label: 10–80 mg10800.1110100mg of monacolin K or lovastatin (log scale)Log-scale chart: monacolin K measured in 26 US red yeast rice brands, 0.09 to 5.48 mg per 1,200 mg of product, against the lovastatin label's dosing range of 10 to 80 mg per dayRed yeast rice, 26 brands: monacolin K per 1,200 mgproductRed yeast rice, 26 brands: 0.09–5.48 mg0.095.48Lovastatin label: range per day; starting dose 20 mgLovastatin label: 10–80 mg10800.1110100mg of monacolin K or lovastatin (log scale)
NCCIH, “Red Yeast Rice” (last updated November 2022): a 2017 review of 28 US brands found no monacolin K in 2 and 0.09–5.48 mg per 1,200 mg in 26; none stated the quantity on the label. Lovastatin tablets label, Dosage and Administration: usual starting dose 20 mg once daily, range 10–80 mg/day. Different bases (per 1,200 mg of product; per day); shown for scale, not as a dose comparison.
Fungal medicines and milestones
FungusMoleculeMilestone
Penicillium notatumPenicillinEffect observed 1928; Nobel Prize 1945
Penicillium citrinumCompactin (ML-236B)Found 1972 in a culture isolated from a rice sample from a Kyoto grain shop
Monascus ruber; Aspergillus terreusMonacolin K = mevinolin = lovastatinBoth isolated February 1979; FDA approval August 31, 1987 (Mevacor)
Beauveria niveaCyclosporine, cyclic peptide of 11 amino acidsFDA November 14, 1983 (Sandimmune)

Fleming A. Nobel lecture, December 11, 1945, and Nobel biography; Endo A. Proc Jpn Acad Ser B 2010;86:484–493; NCCIH (FDA position, warning letters); Drugs@FDA NDAs 019643 and 050573; Sandimmune label.

Botanical drugs

The four botanical drugs

A botanical drug keeps the plant mixture as the active ingredient instead of one purified molecule. FDA lists four approved as prescription drugs: three NDAs and one BLA. Each label defines the mixture by plant species, plant part and measured composition ranges, which is how batch-to-batch consistency is written into an approval.

The four FDA-approved botanical drugs: plant, drug substance, approval and indication
DrugPlant and partDrug substance, as the label defines itFDA approvalIndication
Veregen (sinecatechins) ointment 15%Camellia sinensis, leafPartially purified water extract; catechins 85–95% by weight, of which epigallocatechin gallate more than 55%October 31, 2006External genital and perianal warts
Mytesi (crofelemer) 125 mg delayed-release tabletCroton lechleri, red latexOligomeric proanthocyanidin mixture; average degree of polymerization 5 to 7.5December 31, 2012Non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy
NexoBrid (anacaulase-bcdb) topical gelAnanas comosus, stemProteolytic enzyme mixture, 80–95% w/w proteins (stem bromelain, ananain, others)December 28, 2022 (BLA)Eschar removal in deep partial- and full-thickness thermal burns
Filsuvez (birch triterpenes) topical gel 10%Betula pendula, B. pubescens and hybrids, barkRefined dry extract: betulin 72–88%, lupeol 2.4–5.7%, betulinic acid 2.6–4.2%, erythrodiol 0.5–1.2%, oleanolic acid 0.3–0.8% (w/w)December 18, 2023Wounds of dystrophic and junctional epidermolysis bullosa, 6 months and older

FDA, “What is a Botanical Drug?” (content current as of September 3, 2026); Veregen, Mytesi, NexoBrid and Filsuvez labels (Description, Indications); Drugs@FDA NDAs 021902, 202292, 215064 and BLA 761192. Filsuvez: FDA Drug Trials Snapshot (EASE phase 3, NCT03068780, 223 patients at 49 sites in 26 countries); EU approval June 21, 2022.

FDA received 739 botanical INDs from March 1984 to December 2020, most outside oncologyFDA authors, 2025
Horizontal bars: 254 oncology and 485 non-oncology botanical INDs from March 1984 to December 2020, 739 in allOncology botanical INDs, 1984–2020Oncology botanical INDs, 1984–2020: 254254Non-oncology botanical INDs, 1984–2020Non-oncology botanical INDs, 1984–2020: 485485All botanical INDs, 1984–2020All botanical INDs, 1984–2020: 7397390200400600800Horizontal bars: 254 oncology and 485 non-oncology botanical INDs from March 1984 to December 2020, 739 in allOncology botanical INDs, 1984–2020Oncology botanical INDs, 1984–2020: 254254Non-oncology botanical INDs, 1984–2020Non-oncology botanical INDs, 1984–2020: 485485All botanical INDs, 1984–2020All botanical INDs, 1984–2020: 7397390200400600800
IND counts, March 1984 to December 2020: Ther Innov Regul Sci 2025 (FDA authors; PMC12446141), which attributes the low yield to chemistry, manufacturing and controls (batch consistency) and to efficacy. Approvals: FDA botanical drug page (four, through 2023). The two counts cover different products and periods, so they are not an approval rate. Other FDA counts (“over 400” since 2004; more than 600 pre-INDs and INDs) use other definitions and dates.
For botanicals

What the record teaches

In 18 of the 22 approvals in the reference table, the active ingredient is one defined molecule or, for Coartem, a fixed pair; many of these are now made by semi-synthesis, synthesis or fermentation. The four botanical drugs kept the mixture and had to specify it by species, part and composition range. Lovastatin shows the reverse effect: a drug approved first keeps that molecule out of supplements.

Lessons from the record and the primary evidence for each
ObservationEvidence on this page
The extraction method can decide whether activity is seenCold ether extraction of A. annua gave consistent 100% parasite killing in animals where earlier extracts gave 12–40% (Nobel background)
Supply moves from harvest to synthesis or semi-synthesisPaclitaxel, etoposide, eribulin, trabectedin, ziconotide, capsaicin labels
Few botanical mixtures have reached approvalFour approved under an NDA or BLA (2006–2023); FDA authors name CMC and efficacy as the obstacles
First lawful use decides the channelLovastatin approved as a drug in 1987; lovastatin-enhanced red yeast rice excluded from supplements (21 USC 321(ff)(3)(B); NCCIH)
Exclusivity ends and revenue followsTaxol: US exclusivity to December 1997; sales down 25% in 2001 with generic competition

Sources as cited in each section. Statute: 21 USC 321(ff)(3)(B). The claims a supplement may and may not make, and why, are on The claims gap.

EUTECNIQ Proposed

Where EUTECNIQ would work

EUTECNIQ would apply the parts of this record that a botanical program controls: extraction conditions chosen by measurement, identity and composition ranges written as specifications, and early decisions on whether an ingredient belongs in the supplement or the drug channel. It has no drug programs, laboratory or data today.

Related pages: The claims gap · Pipeline · Extraction · Purification and standardization · History of botanical medicine · Natural vs synthetic

Health information notice

These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.

Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to check what you take?

Free tools built on published reference values, each with its sources and its limits. Your lists stay in your browser.